Top-News

Allarity Therapeutics News

Aktie
WKN:  A3D7BF ISIN:  US0167442039 US-Symbol:  MDIPF
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
296,57 Tsd.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.03.2023

Allarity Therapeutics News

09.01.24 - wallstreet:online Zentralredaktion
Hohe Leerverkaufsquote: Das sind die zehn meistgehassten Aktien an der Wall Street
Ungeachtet des freundlichen Gesamtmarktes kommen einige Papiere nicht auf die Beine: Hier haben Short-​Seller ihre Finger im Spiel. Diese zehn Aktien sind die Papiere mit dem ...
23.01.23 - PR Newswire
Thinking about buying stock in Helbiz, General Electric, Allarity Therapeutics, Bed Bath & Beyond, or Lucid Group?
Thinking about buying stock in Helbiz, General Electric, Allarity Therapeutics, Bed Bath & Beyond, or Lucid Group? PR Newswire
18.10.22 - DGAP
EQS-News: Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform
EQS-News: Allarity Therapeutics, Inc. Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-​Generation” Diagnostics Platform 18.10.2022 / 14:00 ...
26.08.22 - PR Newswire
Thinking about buying stock in Cassava Sciences, Allarity Therapeutics, Nio, Roblox, or Verona Pharma?
Thinking about buying stock in Cassava Sciences, Allarity Therapeutics, Nio, Roblox, or Verona Pharma? PR Newswire
25.08.22 - PR Newswire
Thinking about buying stock in FREYR Battery, Destination XL, Figs Inc, Allarity Therapeutics, or Party City?
Thinking about buying stock in FREYR Battery, Destination XL, Figs Inc, Allarity Therapeutics, or Party City? PR Newswire
22.04.22 - GlobeNewswire
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Cambridge, MA U.S.A. ( April 22 , 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-​stage pharmaceutical company developing novel oncology ...
15.03.22 - GlobeNewswire
Allarity Therapeutics Provides Update on Dovitinib Program
FOR IMMEDIATE RELEASE
03.01.22 - GlobeNewswire
Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
Press release
23.09.21 - GlobeNewswire
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate
16.09.21 - GlobeNewswire
Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress
23.08.21 - GlobeNewswire
Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq
26.01.21 - GlobeNewswire
Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus
Press Release
09.12.20 - DGAP
Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture
Edison Investment Research Limited Allarity Therapeutics (ALLR): A new direction and name for Oncology Venture 09-Dec-2020 / 08:46 GMT/BST London, UK, 9 December 2020 ...
21.09.20 - GlobeNewswire
Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy
Hørsholm, Denmark (21 September 2020) – Oncology Venture A/S (“OV”) today announced that it will change its company name to Allarity Therapeutics (“Allarity” or the “Company”) and ...
26.08.20 - GlobeNewswire
Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies
-Company to advance Stenoparib into human clinical trials as a potential therapy for COVID-19
29.06.20 - GlobeNewswire
Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy
Hørsholm, Denmark (29 June 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that it has signed a definitive agreement out-​licensing two clinical pipeline ...
22.04.20 - GlobeNewswire
Press release Oncology Venture to test activity of its PARP inhibitor, 2X-121, as a potential therapy for Coronavirus
Hørsholm, Denmark (April 22 nd , 2020) – Oncology Venture A/S (“OV” or the Company) today announced that it has entered into an agreement with the Pathogen and Microbiome ...
20.03.20 - GlobeNewswire
Press release Oncology Venture receives feedback from U.S. FDA on potential approval pathway for Dovitinib.
Hørsholm, Denmark (20 March 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that it has received feedback from its recent pre-NDA meeting with the U.S. FDA ...
04.06.19 - GlobeNewswire
OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal
Investor News
26.04.19 - GlobeNewswire
Oncology Venture Investor Events in Q2 2019 – new event
Investor news

Newssuche

Videos

newspaper
08:55 Uhr -10,92%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »